Yokoyama H, Kawai K, Kobayashi M, on behalf of the Japan Diabetes Clinical Data Management Study Group: Microalbuminuria is common in Japanese type 2 diabetic patients: a nationwide survey from the Japan Diabetes Clinical Data Management Study Group (JDDM 10). Diabetes Care 30:989–992, 2007
In Table 1 of the above-listed article, values in the “Glomerular filtration rate <60 (%)” row were incorrect. The corrected table appears on the following page.
Table 1—
Clinical characteristics of subjects
| . | Total . | Stage I . | Stage II . | Stage III . | Stage IV . | Stage V . | P . | Data availability . |
|---|---|---|---|---|---|---|---|---|
| n (%) | 8,897 | 5,152 (58) | 2,812 (32) | 657 (7) | 242 (2.6) | 34 (0.4) | ||
| Age (years) | 63 ± 11 | 61 ± 11 | 64 ± 11 | 67 ± 12 | 69 ± 11 | 63 ± 12 | <0.0001 | 100 |
| Male | 66 | 66 | 63 | 72 | 70 | 82 | <0.0001 | 100 |
| BMI (kg/m2) | 24.3 ± 3.8 | 24.1 ± 3.7 | 24.7 ± 4.0 | 25.1 ± 4.1 | 23.8 ± 3.9 | 23.9 ± 4.0 | <0.0001 | 100 |
| Count of ACR measurements (3/2/1/0) | 3,209/2,006/3,167/239 (37/23/37/3) | 2,091/1,308/1,753/0 (41/25/34/0) | 950/627/1,235/0 (34/22/44/0) | 168/71/179/239 (26/11/27/36) | — | — | ||
| Duration (years) | 12 ± 9 | 11 ± 8 | 12 ± 8 | 15 ± 10 | 17 ± 11 | 17 ± 11 | <0.0001 | 100 |
| A1C (%) | 7.1 ± 1.2 | 6.9 ± 1.1 | 7.3 ± 1.3 | 7.4 ± 1.3 | 6.7 ± 1.2 | 6.5 ± 2.5 | <0.0001 | 99.8 |
| Diet/tablet/insulin | 19/57/24 | 23/59/18 | 15/59/26 | 9/49/42 | 14/36/50 | 15/12/73 | <0.0001 | 100 |
| Hypertension* | 61 | 52 | 68 | 85 | 92 | 79 | <0.0001 | 99.5 |
| Systolic blood pressure (mmHg) | 130 ± 17 | 127 ± 15 | 133 ± 16 | 137 ± 19 | 139 ± 22 | 139 ± 16 | <0.0001 | 99.3 |
| Diastolic blood pressure (mmHg) | 75 ± 11 | 75 ± 10 | 76 ± 11 | 76 ± 12 | 74 ± 12 | 75 ± 10 | <0.0001 | 99.3 |
| Serum creatinine (μmol/l) | 80 ± 66 | 66 ± 16 | 69 ± 19 | 106 ± 40 | 301 ± 120 | 770 ± 179 | <0.0001 | 92.1 |
| Glomerular filtration rate (ml/min per 1.73 m2) | 66.6 ± 18.2 | 71.1 ± 13.5 | 67.8 ± 15.5 | 50.4 ± 19.8 | 17.0 ± 6.9 | 5.9 ± 1.6 | <0.0001 | 92.1 |
| Glomerular filtration rate <60 (%) | 28 | 18 | 30 | 67 | 100 | 100 | <0.0001 | 92.1 |
| Antihypertensive agentsusage (0/1/2/3) | 49/26/16/9 | 57/25/13/5 | 44/30/18/8 | 24/25/28/23 | 16/17/28/39 | 29/24/18/29 | <0.0001 | 100 |
| ARB or ACE inhibitor | 2,964 (33) | 1,452 (28) | 986 (35) | 380 (58) | 133 (55) | 13 (38) | <0.0001 | |
| CCB | 3,044 (34) | 1,391 (27) | 1,114 (40) | 356 (54) | 166 (69) | 17 (50) | <0.0001 | |
| β-Blockers | 504 (6) | 220 (4) | 194 (7) | 56 (9) | 30 (12) | 4 (12) | <0.0001 | |
| α-Blockers | 254 (3) | 105 (2) | 73 (3) | 37 (6) | 35 (15) | 4 (12) | <0.0001 | |
| Diuretics | 819 (9) | 351 (7) | 193 (7) | 154 (23) | 106 (44) | 15 (44) | <0.0001 | |
| Triglycerides (mmol/l) | 1.68 ± 1.33 | 1.57 ± 2.23 | 1.75 ± 1.59 | 2.07 ± 1.68 | 1.93 ± 1.16 | 2.16 ± 2.22 | <0.0001 | 94.4 |
| Total cholesterol (mmol/l) | 5.1 ± 1.0 | 5.1 ± 0.8 | 5.1 ± 0.9 | 5.3 ± 1.1 | 5.1 ± 1.4 | 4.7 ± 1.2 | <0.0001 | 89.8 |
| HDL cholesterol (mmol/l) | 1.4 ± 0.4 | 1.4 ± 0.4 | 1.4 ± 0.4 | 1.3 ± 0.4 | 1.2 ± 0.4 | 1.4 ± 0.5 | <0.0001 | 88.5 |
| Antihyperlipidemic agents (0/1/2) | 66/32/2 | 68/31/1 | 65/33/2 | 63/34/3 | 53/44/3 | 62/38/0 | <0.0001 | 100 |
| Use of aspirin | 11 | 8 | 13 | 18 | 19 | 18 | <0.0001 | 100 |
| Attainment of goals | ||||||||
| A1C <6.5% | 31 | 35 | 26 | 21 | 42 | 62 | <0.0001 | |
| Blood pressure <130/80 mmHg | 42 | 48 | 34 | 29 | 27 | 24 | <0.0001 | |
| Total cholesterol <5.2 mmol/l | 55 | 55 | 55 | 49 | 60 | 67 | 0.029 | |
| Triglycerides <1.68 mmol/l | 63 | 67 | 64 | 50 | 50 | 63 | <0.0001 | |
| HDL cholesterol >1.03 mmol/l | 83 | 85 | 84 | 75 | 63 | 65 | <0.0001 |
| . | Total . | Stage I . | Stage II . | Stage III . | Stage IV . | Stage V . | P . | Data availability . |
|---|---|---|---|---|---|---|---|---|
| n (%) | 8,897 | 5,152 (58) | 2,812 (32) | 657 (7) | 242 (2.6) | 34 (0.4) | ||
| Age (years) | 63 ± 11 | 61 ± 11 | 64 ± 11 | 67 ± 12 | 69 ± 11 | 63 ± 12 | <0.0001 | 100 |
| Male | 66 | 66 | 63 | 72 | 70 | 82 | <0.0001 | 100 |
| BMI (kg/m2) | 24.3 ± 3.8 | 24.1 ± 3.7 | 24.7 ± 4.0 | 25.1 ± 4.1 | 23.8 ± 3.9 | 23.9 ± 4.0 | <0.0001 | 100 |
| Count of ACR measurements (3/2/1/0) | 3,209/2,006/3,167/239 (37/23/37/3) | 2,091/1,308/1,753/0 (41/25/34/0) | 950/627/1,235/0 (34/22/44/0) | 168/71/179/239 (26/11/27/36) | — | — | ||
| Duration (years) | 12 ± 9 | 11 ± 8 | 12 ± 8 | 15 ± 10 | 17 ± 11 | 17 ± 11 | <0.0001 | 100 |
| A1C (%) | 7.1 ± 1.2 | 6.9 ± 1.1 | 7.3 ± 1.3 | 7.4 ± 1.3 | 6.7 ± 1.2 | 6.5 ± 2.5 | <0.0001 | 99.8 |
| Diet/tablet/insulin | 19/57/24 | 23/59/18 | 15/59/26 | 9/49/42 | 14/36/50 | 15/12/73 | <0.0001 | 100 |
| Hypertension* | 61 | 52 | 68 | 85 | 92 | 79 | <0.0001 | 99.5 |
| Systolic blood pressure (mmHg) | 130 ± 17 | 127 ± 15 | 133 ± 16 | 137 ± 19 | 139 ± 22 | 139 ± 16 | <0.0001 | 99.3 |
| Diastolic blood pressure (mmHg) | 75 ± 11 | 75 ± 10 | 76 ± 11 | 76 ± 12 | 74 ± 12 | 75 ± 10 | <0.0001 | 99.3 |
| Serum creatinine (μmol/l) | 80 ± 66 | 66 ± 16 | 69 ± 19 | 106 ± 40 | 301 ± 120 | 770 ± 179 | <0.0001 | 92.1 |
| Glomerular filtration rate (ml/min per 1.73 m2) | 66.6 ± 18.2 | 71.1 ± 13.5 | 67.8 ± 15.5 | 50.4 ± 19.8 | 17.0 ± 6.9 | 5.9 ± 1.6 | <0.0001 | 92.1 |
| Glomerular filtration rate <60 (%) | 28 | 18 | 30 | 67 | 100 | 100 | <0.0001 | 92.1 |
| Antihypertensive agentsusage (0/1/2/3) | 49/26/16/9 | 57/25/13/5 | 44/30/18/8 | 24/25/28/23 | 16/17/28/39 | 29/24/18/29 | <0.0001 | 100 |
| ARB or ACE inhibitor | 2,964 (33) | 1,452 (28) | 986 (35) | 380 (58) | 133 (55) | 13 (38) | <0.0001 | |
| CCB | 3,044 (34) | 1,391 (27) | 1,114 (40) | 356 (54) | 166 (69) | 17 (50) | <0.0001 | |
| β-Blockers | 504 (6) | 220 (4) | 194 (7) | 56 (9) | 30 (12) | 4 (12) | <0.0001 | |
| α-Blockers | 254 (3) | 105 (2) | 73 (3) | 37 (6) | 35 (15) | 4 (12) | <0.0001 | |
| Diuretics | 819 (9) | 351 (7) | 193 (7) | 154 (23) | 106 (44) | 15 (44) | <0.0001 | |
| Triglycerides (mmol/l) | 1.68 ± 1.33 | 1.57 ± 2.23 | 1.75 ± 1.59 | 2.07 ± 1.68 | 1.93 ± 1.16 | 2.16 ± 2.22 | <0.0001 | 94.4 |
| Total cholesterol (mmol/l) | 5.1 ± 1.0 | 5.1 ± 0.8 | 5.1 ± 0.9 | 5.3 ± 1.1 | 5.1 ± 1.4 | 4.7 ± 1.2 | <0.0001 | 89.8 |
| HDL cholesterol (mmol/l) | 1.4 ± 0.4 | 1.4 ± 0.4 | 1.4 ± 0.4 | 1.3 ± 0.4 | 1.2 ± 0.4 | 1.4 ± 0.5 | <0.0001 | 88.5 |
| Antihyperlipidemic agents (0/1/2) | 66/32/2 | 68/31/1 | 65/33/2 | 63/34/3 | 53/44/3 | 62/38/0 | <0.0001 | 100 |
| Use of aspirin | 11 | 8 | 13 | 18 | 19 | 18 | <0.0001 | 100 |
| Attainment of goals | ||||||||
| A1C <6.5% | 31 | 35 | 26 | 21 | 42 | 62 | <0.0001 | |
| Blood pressure <130/80 mmHg | 42 | 48 | 34 | 29 | 27 | 24 | <0.0001 | |
| Total cholesterol <5.2 mmol/l | 55 | 55 | 55 | 49 | 60 | 67 | 0.029 | |
| Triglycerides <1.68 mmol/l | 63 | 67 | 64 | 50 | 50 | 63 | <0.0001 | |
| HDL cholesterol >1.03 mmol/l | 83 | 85 | 84 | 75 | 63 | 65 | <0.0001 |
Data are n (%), means ± SD, or percentages unless otherwise indicated.
*
Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or taking antihypertensives. Glomerular filtration rate 186 × (Scr + 0.2)−1.154 × age−0.203 × 0.742 (if female) × 0.881 (by the Modification of Diet in Renal Disease method refitted for Japanese patients). CCB, calcium channel blocker.
DIABETES CARE
2007
